- Avanir Pharmaceuticals (AVNR +2.2%) reaches an agreement with Sandoz that will allow the latter to start selling generic versions of Avanir's Nuedexta drug from mid-2026 or earlier under certain circumstances.
- Avanir will now drop its lawsuit against Sandoz, although not against four other companies who want to sell copycat versions of Nuedexta, which treats MS and Lou Gehrig patients for bouts of uncontrolled laughter and crying. (PR)